Search

Displaying results 811 - 820 of 4188 in total
  1. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  2. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].

  3. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...

  4. Drug

    Vindesine

    go.drugbank.com/drugs/DB00309
    ApprovedInvestigationalWithdrawn

    Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

  5. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.

  6. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.

  7. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.

  8. Drug

    Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB16901
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16904
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16916
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.